50.55
0.36%
+0.18
After Hours:
50.55
Globus Medical Inc stock is currently priced at $50.55, with a 24-hour trading volume of 532.95K.
It has seen a +0.36% increased in the last 24 hours and a -2.07% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $50.60 pivot point. If it approaches the $49.79 support level, significant changes may occur.
Previous Close:
$50.37
Open:
$50.6
24h Volume:
532.95K
Market Cap:
$6.84B
Revenue:
$1.57B
Net Income/Loss:
$122.87M
P/E Ratio:
25.15
EPS:
2.01
Net Cash Flow:
$165.23M
1W Performance:
+0.40%
1M Performance:
-2.07%
6M Performance:
+9.25%
1Y Performance:
-12.33%
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 General Armistead Avenue, Audubon, PA
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-20-23 | Initiated | ROTH MKM | Buy |
Sep-19-23 | Upgrade | Stifel | Hold → Buy |
Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
Feb-10-23 | Downgrade | Needham | Buy → Hold |
Feb-10-23 | Downgrade | Truist | Buy → Hold |
Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Buy |
Apr-13-22 | Resumed | Truist | Buy |
Mar-28-22 | Initiated | Wells Fargo | Overweight |
Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
Oct-29-21 | Initiated | Loop Capital | Buy |
Feb-18-21 | Resumed | Needham | Buy |
Dec-08-20 | Initiated | Citigroup | Buy |
Oct-20-20 | Initiated | Stifel | Hold |
Aug-06-20 | Reiterated | Needham | Buy |
Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
Jul-21-20 | Initiated | Northland Capital | Market Perform |
Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
May-08-20 | Reiterated | Needham | Buy |
Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
Jan-08-20 | Initiated | SunTrust | Buy |
Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Aug-02-19 | Reiterated | Needham | Buy |
May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
May-03-19 | Reiterated | Needham | Buy |
Feb-28-19 | Upgrade | UBS | Neutral → Buy |
Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-02-18 | Reiterated | Needham | Buy |
Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
May-03-18 | Reiterated | Needham | Buy |
Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
GMED vs. PEN: Which Stock Is the Better Value Option?
Zacks Investment Research
Globus Medical Schedules First Quarter Earnings Release and Conference Call
GlobeNewswire Inc.
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
Zacks Investment Research
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
Zacks Investment Research
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks Investment Research
Globus Medical (GMED) Down 5.8% Since Last Earnings Report: Can It Rebound?
Zacks Investment Research
Globus Medical Inc Stock (GMED) Financials Data
Globus Medical Inc (GMED) Revenue 2024
GMED reported a revenue (TTM) of $1.57 billion for the quarter ending December 31, 2023, a +53.34% rise year-over-year.
Globus Medical Inc (GMED) Net Income 2024
GMED net income (TTM) was $122.87 million for the quarter ending December 31, 2023, a -35.39% decrease year-over-year.
Globus Medical Inc (GMED) Cash Flow 2024
GMED recorded a free cash flow (TTM) of $165.22 million for the quarter ending December 31, 2023, a +58.23% increase year-over-year.
Globus Medical Inc (GMED) Earnings per Share 2024
GMED earnings per share (TTM) was $1.17 for the quarter ending December 31, 2023, a -37.10% decline year-over-year.
About Globus Medical Inc
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum. The company's disruptive technology products comprise products that allow for minimally invasive surgical techniques; and new treatment alternatives, including imaging, navigational, and robotic technologies, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous process spacer products. Its disruptive technology products also consist of regenerative biologics products, including bioactive glass-based bone void fillers and ceramic-collagen for pelvic/extremity and posterolateral spinal fusion procedures; and interventional pain management solutions, which comprise treatments for vertebral compression fractures. In addition, the company offers products for the treatment of orthopedic trauma, including compression screws, fixation plates, intramedullary nails, and external fixation systems. Further, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Cap:
|
Volume (24h):